stockrow
Friday 6 November 2026
Export HCAT’s income statement to Excel — free account
Health Catalyst, Inc.
HCAT Healthcare Health Information Services
Health Catalyst, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $311.1 million, up 1.48% from fiscal 2024.
- Revenue
- −26.3%
- EPS
- +268.8%
- Free cash flow
- +65.6%
- Total debt
- +0.29%
Quarter to September 2026, against a year earlier
1.47
0.03
−2.00%
Follow HCAT
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.48 | 0.50 | 0.30 | 0.54 | |
P/FCF ratio |
24.09 | 22.35 | 0.00 | 0.00 | |
P/Operating CF |
(70.06) | 535.20 | 4.98 | 16.85 | |
P/B ratio |
0.90 | 1.46 | 0.67 | 0.68 | |
Price to Tangible BV |
1.56 | 4.38 | 0.00 | 0.00 | |
EV/Sales |
0.76 | 0.67 | 0.45 | 0.72 | |
EV/EBITDA |
23.30 | 22.32 | 11.39 | 62.48 | |
EV/Operating CF |
7.67 | 6.99 | 7.21 | 307.21 | |
EV/FCF |
37.76 | 29.95 | (50.38) | (10.81) | |
Quick Ratio |
1.54 | 1.58 | 1.56 | 1.73 | |
Current Ratio |
1.70 | 2.70 | 1.69 | 1.89 | |
Net Debt/EBITDA |
0.00 | 24.21 | 25.14 | 6.34 | |
Debt/Assets |
0.00% | 42.80% | 37.21% | 30.49% | |
Debt/Equity |
0.00 | 1.52 | 1.11 | 0.62 | |
Asset Turnover |
0.66 | 0.60 | 0.46 | 0.46 | |
Operating CF/Net income |
(0.05) | (0.01) | (0.17) | (0.11) | |
Capex/Depreciation |
0.00 | (0.14) | (0.05) | (0.06) | |
Interest Coverage |
92.85 | (9.75) | (25.75) | (18.85) | |
Research and Development Expense of Revenue |
16.88% | 15.64% | 13.82% | 13.27% | |
Selling, General and Administrative Expense of Revenue |
36.53% | 31.62% | 34.69% | 28.41% | |
Intangible Assets out of Total Assets |
0.26 | 0.19 | 0.44 | 0.57 | |
Share Based Compensation of Revenue |
7.24% | 3.84% | 5.33% | 5.50% | |
Graham Net Nets |
0.31 | (0.06) | (1.00) | (0.52) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(163.01%) | (184.92%) | (292.91%) | (106.28%) | |
Free Cash Flow Yield |
4.15% | 4.47% | (2.94%) | (12.44%) | |
Revenue per Share |
0.74 | 0.95 | 0.97 | 1.07 | |
Operating CF per Share |
(0.02) | 0.00 | 0.26 | 0.14 | |
Capex per Share |
0.00 | (0.07) | (0.08) | (0.08) | |
Free Cash Flow per Share |
(0.03) | (0.07) | 0.18 | 0.06 | |
Cash per Share |
1.04 | 1.40 | 1.50 | 1.37 | |
Shareholders Equity per Share |
1.92 | 1.36 | 1.90 | 3.52 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.92 | 1.36 | 1.90 | 3.52 | |
Free Cash Flow |
(1.92) | (5.17) | 13.02 | 4.33 | |
Working Capital |
54.82 | 156.47 | 74.70 | 79.73 | |
Capital Expenditures |
(0.05) | (5.45) | (5.49) | (5.58) | |
Net Current Asset Value |
41.13 | (9.39) | (91.74) | (87.56) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.08 | 0.08 | 0.07 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
50.72 | 55.14 | 61.60 | 58.16 | |
Average Payables |
5.74 | 8.64 | 10.32 | 10.40 | |
Average Assets |
412.27 | 487.39 | 651.87 | 680.79 | |
Average Common Equity |
238.75 | 224.19 | 257.48 | 305.49 |
Columns are period end dates · fundamentals updated 5 Nov 2026